The Clinical Efficacy Analysis Of Different Medication Regimens On Cervical HR-HPV Infection

ObjectiveTo compare the clinical efficacy of recombinant human interferon a-2b vaginal effervescent tablets with recombinant human interferon a-2b vaginal effervescent tablets combined with thymus injection on high-risk HPV infection.MethodsSystem access to the clinical data of patients with HR-HPV)(High risk human PaPilloma virus)of the First Affiliated Hospital of Zhengzhou University from May 2019 to May 2021,strictly followed the inclusion criteria and exclusion criteria,and collected 388 patients with HR-HPV infection,including 260 patients with single HPV infection and 128 patients with multiple infection.According to the selected treatment methods,they were divided into three groups:115 patients in group A,none of which used drug intervention;176 patients in group B were treated with recombinant human interferon a-2b vaginal effervescent tablets(Jin Shu xi);97 patients in group C were treated with recombinant human interferon a-2b and thymus injection.All groups were reviewed six months later to analyze and compare HPV-DNA,TCT and colposcopy biopsy before and after treatment.Statistical analysis of the obtained case data was performed using SPSS21.0 software.Measurement data are expressed as mean ± standard deviation(χ±S),compared using one-way ANOVA.Enumeration data were expressed as the number of cases or rate(%).Multiple-categorized ordered data were compared using the rank-sum test.Two classification data were compared using the chi-square(χ2)test.At P<0,05,the comparisons were statistically different between the respective groups.Results1.A total of 388 patients were collected in this study,aged 20-69 years,with an average age of 41.67±10.84 years.Pregnant 0-5 times,the average pregnant 2.45±1.18 times.Childbearing 0-4 parities,and an average parity of 1.60±0.86.The infection time was 1-12 months,and the average infection time was 5.32±3.02 months.There was no statistical significance in the general data of each group(P>0.05).2.Out of 260 patients with single HPV infection,the most common HPV genotypes were HPV52,16,58.Double infection is the most common infection in 128 patients multiple HPV infections.There was no significant difference in the distribution of HPV infection in the three groups.The TCT findings in the three group cases suggested 122 cases of LSIL.And the TCT distribution was generally identical among the three groups(P>0.05).3.The HPV-DNA outcome of each group after treatment:The negative con version rate,obvious efficiency and inefficiency of group A were 27%,10.4%and 62.6%.And the negative conversion rate,obvious efficiency and inefficien cy of group B were 35.2%,19.3%and 45.5%.The negative conversion rate,o bvious efficiency and inefficiency in group C were 73.2%,13.4%and 13.4%,respectively.The rank sum test was used to compare the clinical efficacy of th e three groups,and the difference was statistically significant(P<0.05).The tre atment effects on HR-HPV were different or not identical among the three trea tment groups.Further pairwise comparisons were performed,and there were sta tistically significant differences between group A and group B,group A and gr oup C,and group B and group C(P<0.05).4.The HPV-DNA negative conversion rate of each group after treatment:Statistical analysis of the HPV negative rate showed that there was no significant difference between group A and group B(P>0.05).The negative rate of HPV in group C was significantly better than that in group A and group B,and the difference was statistically significant(P<0.05).5.The TCT outcome of each group after treatment:the normal rate of group A was 20.8%(11/53),and the normal rate of group B was 25.0%(23/92).The normal rate in group C was 61.1%(33/54).There was no significant difference in the normal rate of TCT between group A and group B after treatment(P>0.05).The normal rate of TCT in group C was significantly higher than that in group A and group B,and the difference was statistically significant(P<0.05).6.The Pathological outcome of patients with HR-HPV infection complicated with LSIL:The reversal rate of group A was 17.6%(3/17),and the non-progression rate was 82.4%(14/17).There were 15 cases in group B,and the reversal rate was 33.3%(5/15),the progression-free rate was 66.6(10/15).There were 14 cases in group C,the reversal rate was 64.3%(9/14),the progression-free rate was 28.6%(4/14),one case progressed from LSIL to HSIL,and the progression rate was 7.1%.The rank sum test was used to test the therapeutic effect of HR-HPV infectioncombined with LSIL in each group,and none of the differences were statistically significant(P>0.05).7.HR-HPV negative conversion rate of different age stratification in each group:There was no significant difference in the pairwise comparison of HR-HPV negative conversion rate of different age stratification in each group.Conclusions1.Drug intervention therapy for HR-HPV infection patients can effectively promote the clearance of HPV.2.For patients with HR-HPV infection,the combination therapy of recombinant human interferon a-2b vaginal effervescent tablets and thymosin for injection can effectively promote the negative conversion of HPV,and its clinical effect is better than that of interferon alone and natural conversion.